The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival (OS) in patients with EGFR-mutated new diagnosed stage IIIB/IV NSCLC in addiction of exon 19, 18/20 and 21 mutation and in addiction of treatment with tyrosine kinase inhibitor (TKI) or chemotherapy: A subgroup analysis of the REASON trial.
 
Wolfgang Schuette
Honoraria - Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune; Merck Serono (Inst); Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Lilly (Inst); Merck Serono (Inst); Roche/Genentech (Inst)
 
Timo Behlendorf
No Relationships to Disclose
 
Peter Schirmacher
No Relationships to Disclose
 
Wilfried Eberhardt
No Relationships to Disclose
 
Manfred Dietel
No Relationships to Disclose
 
Ute Zirrgiebel
Employment - iOMEDICO
 
Lars Muehlenhoff
Employment - AstraZeneca
 
Michael Thomas
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche